DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds with clinical approval from multiple global regulatory agencies (ApexBio, 2024). The library encompasses diverse mechanisms of action, including receptor modulation and enzyme inhibition, suitable for high-throughput (HTS) and high-content screening (HCS) workflows (Song et al., 2023). Compounds like doxorubicin, metformin, and atorvastatin are included and provided as 10 mM DMSO solutions. The resource is validated for drug repositioning, target identification, and mechanistic studies in oncology and neurodegenerative disease (DZNEP, 2023). Solutions remain stable for 12–24 months at -20°C to -80°C, supporting reproducible translational research.

Biological Rationale

Drug repurposing and rapid target identification are key strategies to accelerate therapeutic discovery, particularly for complex diseases like cancer and neurodegeneration (Song et al., 2023). FDA-approved compound libraries provide access to molecules with established safety and pharmacokinetics, reducing the risk and cost of early-stage development. Mechanistic diversity—spanning receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators—enables broad exploration of biological pathways. For example, carbenoxolone disodium, an HDAC6 inhibitor identified via such screening, demonstrates anti-migratory effects in gastric cancer models (Song et al., 2023). The DiscoveryProbe™ FDA-approved Drug Library supports this approach by offering a regulatory-vetted, ready-to-use compound set for HTS and HCS applications.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds with well-characterized mechanisms. These include:

• Receptor agonists and antagonists: Modulate cell signaling pathways, e.g., beta-blockers, opioid agonists.
• Enzyme inhibitors: Block catalytic activity of enzymes such as kinases, phosphatases, and histone deacetylases (HDACs).
• Ion channel modulators: Alter membrane potentials, impacting neuronal or cardiac function.
• Signal pathway regulators: Influence cascades like MAPK, PI3K/AKT, or EGFR pathways.

Representative compounds include doxorubicin (DNA intercalator), metformin (AMPK activator), atorvastatin (HMG-CoA reductase inhibitor), and carbenoxolone disodium (HDAC6 inhibitor; IC50 = 0.772 μM for HDAC6 in biochemical assays, 37°C, pH 7.4) (Song et al., 2023). This diversity allows comprehensive interrogation of cellular targets and processes relevant to disease models.

Evidence & Benchmarks

• Carbenoxolone disodium, present in the DiscoveryProbe™ library, inhibits HDAC6 with an IC50 of 0.772 μM, suppressing migration of MGC-803 gastric cancer cells both in vitro and in vivo (Song et al., 2023).
• FDA-approved compound libraries enable rapid identification of new indications for known drugs, significantly accelerating repurposing timelines (typically reducing early-phase development by 1–3 years) (6-mp.com, 2023).
• Solutions in the DiscoveryProbe™ library are pre-dissolved at 10 mM in DMSO, ensuring reproducibility and compatibility with automated HTS platforms (ApexBio, 2024).
• Compounds maintain stability for at least 12 months at -20°C and 24 months at -80°C, supporting long-term screening campaigns (ApexBio, 2024).

This article extends the mechanistic focus of our previous summary by detailing evidence from recent HDAC6 inhibitor studies, and it clarifies workflow best practices beyond the overview in DZNEP's translational research feature.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is validated for multiple use cases:

• High-throughput screening (HTS): Enables parallel assay of thousands of compounds for activity against defined targets or phenotypic endpoints.
• High-content screening (HCS): Facilitates multiparametric analysis in cellular models to dissect mechanism-of-action and toxicity profiles.
• Drug repositioning: Allows exploration of new indications for existing molecules, leveraging established safety profiles.
• Pharmacological target identification: Deconvolution of active compounds can reveal novel disease pathways or molecular regulators.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for every assay format: Some molecules may interfere with fluorescence or luminescence readouts due to intrinsic properties.
• FDA approval does not imply universal efficacy: Compounds were approved for specific indications and populations; off-target effects or toxicity may emerge in new contexts.
• Pre-dissolved DMSO solutions require careful storage: Repeated freeze-thaw cycles can degrade some compounds despite recommended storage conditions.
• Library does not cover investigational or preclinical compounds: Only molecules with regulatory approval or pharmacopeia listing are included.
• Mechanistic annotation may lag behind emerging discoveries: Some drugs have pleiotropic actions not fully captured in current documentation.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is optimized for seamless integration into automated HTS and HCS workflows. Compounds are supplied as 10 mM DMSO solutions in 96-well microplates, deep-well plates, or 2D barcoded screw-top tubes. Flexible vialing enables direct transfer to robotic pipetting stations. Storage guidelines recommend -20°C for up to 12 months, or -80°C for up to 24 months. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice for larger formats (ApexBio, 2024).

Primary screening can be performed at concentrations ranging from 1–10 μM, depending on assay sensitivity and endpoint. Counter-screening and secondary validation are facilitated by the library's reproducible format. The library supports both target-based and phenotypic screening approaches, enabling rapid iteration in drug discovery pipelines (Annexin-V-FITC, 2023).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) establishes a robust foundation for high-throughput and high-content drug discovery workflows. Its curated, regulatory-approved compound set accelerates drug repositioning, target identification, and mechanism-of-action studies in oncology, neurodegenerative disease, and beyond. Ongoing benchmarking, including the identification of HDAC6 inhibitors for gastric cancer, underscores its translational value (Song et al., 2023). Future updates to the library may incorporate emerging drugs as they achieve regulatory milestones, further expanding the utility of this resource for biomedical research. For detailed product specifications, refer to the DiscoveryProbe™ FDA-approved Drug Library product page.